Evaluation of concordance of new QuantiFERON-TB Gold Plus platforms for Mycobacterium tuberculosis infection diagnosis in a prospective cohort of household contacts.
Cinthya Ruiz-TaglePatricia GarcíaMariluz HernándezMaria Elvira BalcellsPublished in: Microbiology spectrum (2024)
that affects over 10 million people annually, with over 2 billion people carrying an asymptomatic tuberculosis infection (TBI) worldwide. Currently, TBI diagnosis includes tuberculin skin test and the blood-based interferon-gamma (IFN-γ) release assays, with Qiagen QuantiFERON-TB Gold Plus (QFT) being among those most widely utilized. We evaluated Qiagen's newer QFT platforms commercially available in a prospective cohort of tuberculosis contacts. A substantial agreement was obtained between the current QFT-enzyme-linked immunosorbent assay (ELISA) and the new QFT-chemiluminescence immunoassay (CLIA) platform, although QFT-CLIA provided higher concentrations of IFN-γ, leading to a 16.6% higher positivity rate. We highlight that both platforms may not be directly interchangeable and that further validation is required.
Keyphrases
- mycobacterium tuberculosis
- traumatic brain injury
- pulmonary tuberculosis
- high throughput
- dendritic cells
- immune response
- sensitive detection
- severe traumatic brain injury
- emergency department
- mild traumatic brain injury
- silver nanoparticles
- hiv aids
- mass spectrometry
- hiv infected
- wound healing
- soft tissue
- monoclonal antibody
- adverse drug
- drug induced